MSC 2015103B
Alternative Names: AS-703988; MSC-2015103BLatest Information Update: 22 May 2024
Price :
$50 *
At a glance
- Originator Merck Serono
- Class Antineoplastics; Small molecules
- Mechanism of Action MAP kinase kinase 1 inhibitors; MAP kinase kinase 2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 09 May 2024 Day One Biopharmaceuticals has patents granted for MSC2015103B in Argentina, Austria, Australia, Belgium, Brazil, Canada, Switzerland, China, Czech Republic, Germany, Denmark, Eurasia, Estonia, Spain, Finland, France, United Kingdom, Hong Kong, Croatia, Hungary, Ireland, Israel, India, Iceland, Italy, Korea, Lithuania, Luxembourg, Latvia, North Macedonia, Malta, Mexico, Netherlands, Norway, New Zealand, Philippines, Poland, Portugal, Romania, Russian Federation, Sweden, Singapore, Slovenia, Slovakia, Turkey, Ukraine, and South Africa
- 09 May 2024 Day One Biopharmaceuticals has patents issued for composition of matter and methods of use of MSC2015103B in USA
- 23 Feb 2021 MSC 2015103B licensed to Day One Pharmaceuticals globally